{"denoms":[{"counts":[{"groupId":"OG000","value":"0"}],"units":"Participants"}],"groups":[{"description":"Participants with locally advanced or metastatic ALK-positive tumors were to receive alectinib twice daily (BID) until disease progression, unacceptable toxicity, death, or withdrawal from the study for any reason.","id":"OG000","title":"ALK-positive Solid Tumors"}],"populationDescription":"CNS ORR was defined as the objective tumor response rate (CR or PR) of CNS lesions and could not be calculated due to an insufficient number of participants with the event.","reportingStatus":"POSTED","timeFrame":"Baseline up to 5 years","title":"Central Nervous System (CNS) ORR by BICR Per RECIST v1.1","type":"SECONDARY"}